Ascendis Pharma A/S
ASND- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001612042
In the last 90 days, Ascendis Pharma A/S insiders filed 1 open-market purchase and 2 sales; 313 institutions reported holding it in 13F filings for Q2 2026, worth $17.8B in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Ascendis Pharma A/S changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 177 | 2 | 168 | −7 |
| Shares | 62.0M | 18.8K | 63.2M | +1.26M (+2.0%) |
| Value | $7.27B | $2.21M | $5.88B | −$1.39B (−19.1%) |
2 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (24)
Institutions that held Ascendis Pharma A/S at the end of Q2 2022 but not at the end of Q1 2022.
Sold out (31)
Institutions that held Ascendis Pharma A/S at the end of Q1 2022 and filed for Q2 2022 without it.
Not filed for Q2 2022 yet (2)
Institutions that held Ascendis Pharma A/S at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Parametric Portfolio Associates LLC | 18,743 | $2.20M |
| SJS Investment Consulting Inc. | 86 | $10.0K |